Basiliximab for the therapy of acute T cell-mediated rejection in kidney transplant recipient with BK virus infection: A case report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Lausanne : Frontiers Research Foundation]
    • Subject Terms:
      BK Virus* ; Kidney Diseases*/complications ; Kidney Transplantation*/adverse effects ; Polyomavirus Infections*/diagnosis ; Polyomavirus Infections*/drug therapy; Aged ; Basiliximab ; Creatinine ; Cyclosporine ; Graft Rejection/drug therapy ; Humans ; Male ; Mycophenolic Acid ; Prednisolone ; Prednisone ; T-Lymphocytes
    • Abstract:
      A 66-year-old Chinese man underwent a deceased donor kidney transplantation. Induction-immunosuppressive protocol consisted of basiliximab (BAS) and methyl prednisolone (MP), followed by maintenance immunosuppression with cyclosporin (CsA), mycophenolate mofetil (MMF), and prednisone (PED). The patient's post-transplantation course was almost uneventful, and the graft was functioning well [serum creatinine (Scr) 2.15 mg/dL]. The MMF and CsA doses were decreased 1-month post-operative as the BK virus activation was serologically positive. His Scr was elevated to 2.45 mg/dL 45 days after the transplant. A graft biopsy showed BKV nephropathy (BKVN) and acute T cell-mediated rejection (TCMR) Banff grade IIA (I2, t2, ptc2, v1, c4d1, g0, and SV40 positive). The conventional anti-rejection therapy could deteriorate his BKVN, therefore, we administered BAS to eliminate activated graft-infiltrating T cells and combined with low-dose steroid. He responded well to the therapy after two doses of BAS were given, and the kidney graft status has been stable (recent Scr 2.1 mg/dL).
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2022 Chen, Li, Wang, Wang, Zhu, Rong and Yang.)
    • References:
      Gastroenterol Hepatol. 2012 Nov;35(9):649-51. (PMID: 22749511)
      N Engl J Med. 1990 Apr 26;322(17):1175-82. (PMID: 2157982)
      Transplant Proc. 2001 May;33(3):2380. (PMID: 11377567)
      Expert Opin Drug Saf. 2014 Mar;13(3):373-81. (PMID: 24266670)
      Transplant Proc. 2014 Apr;46(3):739-43. (PMID: 24767338)
      Cochrane Database Syst Rev. 2017 Jul 20;7:CD004756. (PMID: 28731207)
      Clin Transplant. 2009 Aug;23 Suppl 20:31-3. (PMID: 19594593)
      Clin Transplant. 2019 Sep;33(9):e13528. (PMID: 30859620)
      Am J Transplant. 2020 Sep;20(9):2318-2331. (PMID: 32463180)
      Pediatr Transplant. 2014 Dec;18(8):860-7. (PMID: 25311536)
      Transplantation. 2003 Mar 27;75(6):796-9. (PMID: 12660504)
      Transplant Proc. 2001 Nov-Dec;33(7-8):3213-4. (PMID: 11750379)
      Transplant Proc. 2005 Dec;37(10):4373-9. (PMID: 16387124)
      Biosci Trends. 2011;5(2):57-60. (PMID: 21572248)
      Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. (PMID: 19845597)
      Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):592-7. (PMID: 24928711)
    • Contributed Indexing:
      Keywords: BK virus; acute T cell–mediated rejection; basiliximab; kidney; transplantation
    • Accession Number:
      83HN0GTJ6D (Cyclosporine)
      9927MT646M (Basiliximab)
      9PHQ9Y1OLM (Prednisolone)
      AYI8EX34EU (Creatinine)
      HU9DX48N0T (Mycophenolic Acid)
      VB0R961HZT (Prednisone)
    • Publication Date:
      Date Created: 20221010 Date Completed: 20221011 Latest Revision: 20221012
    • Publication Date:
      20231215
    • Accession Number:
      PMC9537549
    • Accession Number:
      10.3389/fimmu.2022.1017872
    • Accession Number:
      36211389